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Abstract 
Renal dysfunction occurs in 25-50% of patients with cirrhosis admitted to hospital 
with an acute episode of hepatic decompensation and may be due to underlying 
chronic kidney disease, an acute deterioration or both. An acute deterioration in 
renal function in cirrhotic patients is now collectively referred to as acute kidney 
injury (AKI), which has been sub-classified into different grades of severity that 
identifies prognostic groups. Acute on chronic liver failure (ACLF) is characterised by 
acute hepatic and or extrahepatic organ failure driven by a dysregulated immune 
response and systemic inflammatory response. AKI is also one of the defining 
features of ACLF and a major component in grading the severity of ACLF. As such, 
the pattern of AKI now observed in patients admitted to hospital with acutely 
decompensated liver disease is likely to be one of inflammatory kidney injury 
including acute tubular injury (referred in this review as non-HRS-AKI) rather than 
hepatorenal syndrome (HRS). As the management and supportive treatment for non-
HRS-AKI potentially differs from HRS, then from the nephrology perspective it is 
important to distinguish between non-HRS-AKI and HRS-AKI when reviewing 
patients with ACLF and AKI, so that appropriate and early management can be 
instituted. 
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Introduction 
The onset of renal dysfunction in patients with cirrhosis is a frequent occurrence, 
which as a consequence of its association with increased morbidity and mortality 
poses clinicians with a distinct set of intricate challenges from precise recognition 
and diagnosis through to optimal management and treatment paradigms. The recent 
changes in the classification and nomenclature have started to stratify renal 
dysfunction into distinct subgroups defined by the underlying pathophysiology and 
prognosis. The recently published International Club of Ascites (ICA) guidelines have 
suggested that all acute renal dysfunction in patients with cirrhosis be classified 
under the broad heading, acute kidney injury (AKI). 1  
 
The archetypal scenario recognised for several decades is the development of renal 
dysfunction in patients with ascites and advanced cirrhosis,2 a phenomenon 
subsequently termed hepatorenal syndrome (HRS). HRS-AKI is a functional 
syndrome in that the kidneys are typically devoid of parenchymal damage, and 
pathophysiologically the decline in renal function stems from the systemic 
hemodynamic effects of advanced portal hypertension and circulatory dysfunction. 
However, this represents only one aspect of the spectrum of AKI observed in 
cirrhosis. The kidneys can be subject to a multitude of insults in cirrhotic patients 
ranging from pre-renal insults such as hypovolemia to inflammatory tubular injury 
characteristic of sepsis, bile acid nephropathy, drug induced tubular damage; 
collectively now referred to as non-HRS-AKI. Intrinsic renal disease associated with 
the underlying causes of cirrhosis, such as glomerulopathies associated with 
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hepatitis B and C, alcohol and co-morbid conditions of diabetes and hypertension 
are grouped under the term chronic kidney disease (CKD).  
 
Acute on Chronic Liver Failure (ACLF) is a recently recognised clinical entity,3 
distinct from acute decompensation and is characterised by hepatic and one or more 
extrahepatic organ failures associated with increased short term mortality within a 
period of 28 days and up to 3 months from onset (Figure 1).4 Pathophysiologically, 
ACLF stems from a dysregulated immune response to a recognised or unrecognised 
precipitating event.5 AKI is also one of the defining features of ACLF and a major 
component in grading the severity of ACLF.3 The pathophysiological mechanisms 
underlying AKI are poorly characterised in ACLF. This review aims to provide an up 
to date evaluation of the aetiology, pathogenesis and treatment of AKI in ACLF.  
 
Defining AKI 
Old definitions of HRS, its limitations and new definitions 
HRS has often been utilised as an all-encompassing term indicating AKI in patients 
with cirrhosis but with the development of precise criteria to delineate HRS, it now 
only accounts for a small but significant minority of cases of renal dysfunction 
rendering its incidence much less common than traditionally thought. Historically, 
HRS was classified into two types, type 1 and type 2; Type 1 HRS was defined as 
rapid progressive renal failure over two weeks with SCr >2.5mg/dL, whereas type 2 
was associated with a steady progressive course of moderate renal failure (SCr from 
1.5 to 2.5 mg/dL) in patients with refractory ascites.6 It has been widely recognised 
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that in cirrhotic patients, creatinine levels may remain low despite advanced renal 
failure due to sarcopenia and that these criteria are very restrictive in terms of 
allowing earlier institution of therapy. The ICA has more recently proposed new 
diagnostic criteria for HRS in 20151 (Table 1) and the sub-classification of Type 1 
and Type 2 has been withdrawn. In addition, the limiting threshold SCr>2.5mg/dL 
essential to diagnosis has also been removed and HRS is now recognised as a form 
of AKI (HRS-AKI). Similarly, the two-week threshold for diagnosing type 1 HRS has 
also been removed; thus HRS-AKI may now be diagnosed in the context of lack of 
response to plasma volume expansion in a patient who meets ICA-AKI criteria, has 
no recent exposure to nephrotoxic drugs or evidence of shock or signs of structural 
kidney disease. AKI represents a complex multifactorial syndrome encompassing 
different phenotypes of disease, which may be due to a number of pathological 
mechanisms that can overlap and exist concurrently. The definitions of AKI subtypes 
such as HRS-AKI and non-HRS-AKI are, at present, primarily clinical definitions 
based on clinical criteria rather than pathological diagnoses. Thus, they are likely to 
represent phenotypes of AKI where certain pathological mechanisms are more 
prominent.  
 
New definitions of AKI 
Increasing knowledge of the epidemiology of AKI and improved understanding of the 
underlying pathophysiological mechanisms coupled with the critical observation that 
even small changes in renal function can be associated with patient mortality has led 
to redefining criteria for AKI.7 The Acute Kidney Injury Network (AKIN) proposed 
guidelines to define AKI in 2007,8 which was the basis on which AKI defining criteria 
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in cirrhotic patients was recommended by the Acute Dialysis Quality Initiative (ADQI) 
and ICA in 2011.9 AKIN criteria aimed to improve the sensitivity of AKI diagnosis by 
allowing for the diagnosis of AKI to be made by detecting a change in absolute 
serum creatinine (SCr) level of ≥ 0.3 mg/dL (26.5µmol/L) or by a rise in SCr ≥ 50% 
from baseline within a 48 hour period. Several studies have subsequently been 
performed as a means of assessing the utility and performance of the AKIN criteria 
in the cirrhotic population.10-15 The results of these studies validated the AKIN criteria 
as being independently associated with mortality in a stage-dependent manner and 
served as the evidence base on which the ICA proposed their new criteria defining 
AKI in cirrhotic patients (Table 2).1 More recently, it has been proposed that AKI, 
stage 1 patients can be divided into 2 sub-groups, defined by whether their serum 
creatinine is greater or less than 1.5mg/dl. Those patients with AKI stage 1 but a 
serum creatinine of >1.5mg/dl were reported to have mortality rates similar to the 
mortality of patients with AKI stage 2 and it is proposed that these patients be 
referred to as having AKI stage 1B.16 It is however, not clear from this study whether 
the latter patients, i.e. those proposed to have Type 1B AKI have greater underlying 
chronic kidney disease or more severe liver dysfunction, as AKI staging is 
descriptive based on changes in serum creatinine and not underlying 
pathophysiology. Further validation of these criteria is needed before altering the 
current guidelines. 
 
Epidemiology and classification 
AKI occurs in 25-50% patients with cirrhosis admitted to hospital with an episode of 
acute decompensation.11, 17-19 It is a strong predictor of poor survival in both the short 
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and longer term, 25-31% of hospitalized cirrhotics with AKI do not survive their 
admission10, 20 with a one and twelve month mortality rates of 58% and 63%, 
respectively.21 Worsening severity of AKI correlates with higher rates of mortality and 
cirrhosis specific complications including ascites and encephalopathy.10, 22 AKI is 
typically characterized as either pre-renal, renal parenchymal or obstructive in origin. 
Pre-renal causes of AKI such as hypovolaemia (for example due to upper 
gastrointestinal haemorrhage, diuretics or diarrhoea from purgatives), HRS-AKI and 
infection account for 60-70% of AKI.23-26  Infection and or severe systemic 
inflammation, as observed in patients with acute alcoholic hepatitis may additionally 
cause non-HRS-AKI. Intrinsic renal causes such as ischaemic injury resulting in non-
HRS-AKI, acute interstitial nephritis, or glomerulonephritis account for up to 30% of 
AKI with post-renal AKI being a relatively uncommon cause (<1%).23, 25, 27 HRS 
accounts for around 15-20% of AKI in hospitalised patients with cirrhosis.23, 26   
 
Pathophysiology 
HRS-AKI pathogenesis 
A figure describing possible pathophysiological mechanism of HRS-AKI is outlined in 
Figure 2.  
Role of Splanchnic Vasodilation: Traditional pathophysiological explanations of HRS-
AKI are that it is a functional disorder secondary to systemic haemodynamic effects 
of advanced portal hypertension leading to marked renal vasoconstriction. Early 
evidence for its functional nature include resolution in renal function after liver 
transplantation,28 successful transplantation of cadaveric kidneys from patients with 
HRS29 and post mortem examination of the kidneys.29 Cirrhosis disrupts the liver 
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architecture giving rise to an increase in intra-hepatic vascular resistance leading to 
a raised portal pressure, which in turn leads to vasodilatation of the splanchnic 
vascular bed through a number of mediators including nitric oxide and endogenous 
cannabinoids.30 In advanced cases of cirrhosis an increased cardiac output can no 
longer compensate for the decreased systemic vascular resistance caused by 
progressive splanchnic vasodilatation, resulting in a reduced effective circulating 
volume. This in turns lead to activation of the sympathetic nervous system and 
vasoconstrictor systems including Renin-Angiotensin-Aldosterone System (RAAS) 
and later vasopressin, to help maintain circulating volume31 resulting in renal 
vasoconstriction and hypo-perfusion of the kidneys. Vasopressin levels are difficult to 
measure accurately but Copeptin, a fragment of the vasopressin precursor molecule 
which is more  easily measured, has shown to be elevated in decompensated 
cirrhosis more than in compensated cirrhosis.32 Higher Copeptin levels correlate with 
haemodynamic derangement in cirrhosis and are predictive of development AKI and 
associated with worse outcomes.32, 33 Renal vasoconstriction has been 
demonstrated on angiography in the cirrhotic patient with renal failure34 and Doppler 
studies of renal blood flow in cirrhotic patients  with ascites have shown raised 
resistive indices predictive of the development of AKI and HRS.35, 36  Also, renal 
blood flow autoregulation is lost in patients with HRS, implying less renal perfusion 
with the same perfusion pressure.37 Certainly the current treatment concepts of 
HRS-AKI are founded on expanding circulating volume using albumin and 
splanchnic vasoconstrictors and have shown success in improving renal function.38, 
39 However, reversal of the syndrome may not occur in up to 40% of patients40 
indicating the role of additional pathophysiological mechanisms,41 or the 
development of  renal tubular injury.42  
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Cardiac Dysfunction: More than 50% of patients with cirrhosis have abnormal or 
blunted cardiac responsiveness to physiological and pathological stress, termed 
cirrhotic cardiomyopathy, and a lower cardiac output has been reported to predict 
both the development of HRS-AKI and worse prognosis.43 Prescription of non-
selective beta-blockers to patients with ascites may pre-dispose to HRS-AKI and 
worsen prognosis,44, 45 particularly in those with associated Spontaneous Bacterial 
Peritonitis (SBP). The dose of these agents should be titrated to maintain mean 
arterial pressure to avoid HRS-AKI development. 
 
Adrenal Insufficiency: Relative Adrenal Insufficiency (RAI) is reported in 25% of 
decompensated cirrhotics and is more common with advancing disease.46 RAI may 
contribute to cirrhotic cardiomyopathy by down regulation of the number of beta-
adrenergic receptors in the heart and modulating the effect of catecholamines on 
cardiac contractility and vascular tone.47  
 
Inflammation: Systemic Inflammation is an additional critical aspect in the 
pathogenesis of decompensated cirrhosis and plays an important role in organ 
dysfunction associated with ACLF.48 Patients with SBP developing renal impairment 
showed significantly higher levels of the pro-inflammatory cytokines TNFα and IL-6 
at diagnosis of SBP compared to those with normal renal function.49 In a further 
study of cirrhotic patients with renal failure the in-hospital mortality rate was more 
than twice as high in those with the systemic inflammatory response syndrome 
(SIRS) than in those without.50 It is in this group of patients who have evidence of 
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AKI that is precipitated by infection or alcoholic hepatitis, that are more likely to have 
non-HRS-AKI rather than HRS-AKI. 
 
Pathogenesis of non-HRS-AKI  
In order to better understand the pathophysiology on non-HRS-AKI, the concept of 
ACLF is described below. 
 
Acute on Chronic Liver Failure 
Renal function forms a key criterion in the stratification of ACLF severity (Table 3), 
and by definition the majority of patients with grade 1 ACLF have renal dysfunction. 
In the seminal CANONIC study3 of 303 patients with ACLF, 209 (69%) had either 
renal dysfunction or renal failure signifying that renal impairment is a key component, 
and is the most single common organ failure observed in ACLF. The serum 
creatinine cut off >1.5mg/dL used to define renal dysfunction in ACLF probably leads 
to an under appreciation of the true incidence of renal dysfunction in ACLF patients 
(Table 3).  However, in a study of 510 hospitalized patients with acute 
decompensation, the development of ACLF using the CLIF– OF score was found to 
more reliably predict 90-day mortality than AKI using the AKIN criteria  (area under 
the receiving operating characteristic curve=0.72 vs. 0.62, respectively).51 This may 
explained, in part by the CLIF-OF score including measures of non-renal organ 
failure and systemic inflammation,3 and systemic inflammation as measured by white 
cell count and C-reactive protein (CRP) is an independent predictor of mortality in 
ACLF.52 Whereas, changes in serum creatinine concentrations alone do not 
accurately match the severity of AKI , as they are affected by underlying pre-existing 
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kidney damage, changes in volume and creatinine generation rates, and do not take 
into account the underlying pathophysiology.  
 
Currently, there are no epidemiological data in the literature reporting the proportion 
of ACLF patients with HRS-AKI but conversely it is likely that most of the patients 
with HRS-AKI will by definition have ACLF. In all HRS studies prior to the recent ICA 
HRS-AKI diagnostic criteria,1 a serum creatinine >1.5mg/dL was required for the 
diagnosis of HRS, which is also required for ACLF grade 1 with additional organ 
dysfunction. HRS-AKI may therefore be present at the onset of ACLF or indeed 
develop as an additional organ failure during ACLF.  Thus, HRS-AKI currently 
remains uncharacterized in ACLF but these terms are not mutually exclusive and are 
likely to share some underlying pathophysiological mechanisms. Pathogenic 
mechanisms involved in non-HRS-AKI associated with ACLF are described in Figure 
3. 
 
Specific Mechanisms involved in non-HRS-AKI 
Role of Inflammation and bacterial translocation: AKI in ACLF is best characterised 
as a heterogeneous condition with variety of initiating factors including infection, with 
the severity of systemic inflammation and additional organ failures all influencing 
outcomes.53  In the CANONIC study single organ renal failure was associated with 
20% mortality, but mortality was significantly higher when renal failure, defined as a 
serum creatinine ≥1.5 mg/dL) was associated with additional organ failure.3 Similarly 
lack of reversibility of HRS with albumin and terlipressin is associated with higher 
CLIF-OF scores, higher serum bilirubin and non-resolution of infection.54-56 Further 
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evidence for systemic inflammation driving ACLF and organ dysfunction came from a 
study measuring 29 different cytokines and an oxidised form of albumin (human non-
mercaptalbumin 2 [HNA2]), a marker of systemic oxidative stress. Patients with 
ACLF demonstrated higher levels of systemic inflammation markers than non-ACLF 
patients and severity of ACLF at enrolment was strongly associated with systemic 
inflammation as was the course of ACLF.57 Specifically, the presence of renal 
dysfunction in ACLF correlated with IL-6, IL-8, and HNA2 and not with measured 
plasma renin concentrations, a marker for systemic circulatory disturbance, 
suggesting that the deleterious effects of systemic inflammation in the pathogenesis 
of ACLF is mediated predominantly by non-haemodynamic mechanisms. 
 
There is only limited renal biopsy data available in cirrhotic patients, due to the risk of 
bleeding arising from coagulation defects. A retrospective French study assessed 
renal biopsy specimens in 65 cirrhotic patients with unexplained renal impairment 
(deﬁned by serum creatinine >1.5mg/dl).58 18 patients with a with raised serum 
creatinine but with no proteinuria or haematuria demonstrated a variety of renal 
lesions, including chronic tubulointerstitial injury, glomerular injury and vascular injury 
such as endarteritis,58 suggesting that patients deemed as having “functional renal 
failure” will also have renal parenchymal pathology.  Renal biopsies in five patients 
with (non-HRS) AKI  (and ACLF) caused by alcoholic cirrhosis revealed evidence of 
tubular damage with evidence of increased tubular expression of Toll like receptor 
(TLR)4, and caspase-3.59 This increased TLR4 expression in the kidneys was 
reflected in increased urinary excretion of TLR4 protein. In contrast, patients with 
HRS-AKI (some of who also had ACLF by definition) did not show the same changes 
suggesting that they were likely to be pathophysiologically different and the 
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fundamental characteristic of non-HRS-AKI in ACLF patients is likely to be acute 
tubular injury. To an extent, this was further explored in animal models. 
 
Although animal models of ACLF are limited, the application of lipopolysaccharide 
(LPS) to a rat model of cirrhosis (bile-duct ligated) demonstrated renal tubular injury 
with an increased renal expression of TLR4 and caspase-3.60  Pro-inflammatory 
cytokines and LPS can directly cause renal tubular cell apoptosis through caspase 
mediated pathways,61 and it was hypothesised that bacterial gut translocation could 
drive this inflammatory injury (Figure 4). Treatment with norfloxacin in cirrhotic rats 
prior to being given LPS demonstrated attenuation in the renal injury both 
biochemically and histologically.60  Use of norfloxacin in humans as primary 
prophylaxis for SBP delayed the onset of HRS-AKI and improved one-year 
survival.62  Long term use of Rifaximin (>3 months) was also shown to reduce the 
incidence of AKI including HRS-AKI.63, 64 Rifaximin exerts its clinical effects by 
modulation of the metabolic function of the gut microbiota.  
 
Role of Bile acids: Patients with ACLF have elevated serum bilirubin levels 
compared to patients with just acute decompensation without ACLF3 and raised 
concentrations of bilirubin and bile acids may contribute to renal injury through direct 
toxic renal effects and by tubular obstruction.65 A clinic-pathological study of renal 
biopsies in jaundiced patients showed that tubular bile casts were present in 11 of 13 
patients with HRS-AKI65 and were thought to be involved in pathogenesis of renal 
injury rather than being bystander phenomena. This is as yet a little explored 
mechanism of AKI in ACLF but could potentially explain observations of why high 
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bilirubin levels are predictors of poor response to vasoconstrictor therapy in HRS-
AKI.55, 56 Recently, the concept of bile acid nephropathy has been further 
characterised in animal models.66  
 
Role of worsening portal hypertension: ACLF patients have been shown to have 
markedly increased intrahepatic intravascular resistance resulting in increased portal 
pressure, 67  which may contribute to further AKI  through the hepatorenal reflex.68  
 
Role of Cardiac dysfunction and renal hypoperfusion: ACLF patients show evidence 
of severe cardiovascular dysfunction that can manifest both with increased and 
decreased cardiac output that may result in worsening of renal perfusion and 
ischemia.67  Patients with more advanced stages of ACLF also require inotropes 
which may further limit renal perfusion.2,3 
 
Overlap of pathogenic mechanisms of HRS-AKI and non-HRS-AKI in ACLF 
 Although, the pathogenic mechanisms described above suggest that HRS-AKI and 
non-HRS-AKI are distinct sub-types, in reality it is likely that pathogenic mechanisms 
of AKI in ACLF patients have overlapping features (Table 4). It is possible that HRS-
AKI evolves to non-HRS-AKI in the majority of cases. This contention is supported 
by the observations that only about 40% patients respond to terlipressin and 
albumin, and the duration of HRS increases unresponsiveness to these agents with 
time; mortality rates of over 80% despite evidence of temporary resolution in about 
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40% and lack of recovery of kidney function if HRS-AKI persists for over 6-weeks 
(see later). 
 
The most common causes of liver disease such as non-alcoholic fatty liver disease, 
which is associated with diabetes and hypertension; Hepatitis B or Hepatitis C can 
be associated with nephropathy independent of the severity of liver disease. In most 
instances, serum creatinine levels may be within the normal reference range in these 
patients but they have reduced glomerular filtration rate and so are more susceptible 
to acute renal insults. Although these patients have, by definition, acute on chronic 
kidney dysfunction, they are considered to have AKI, by current staging criteria. It is 
also unclear as to whether increasing severity of liver disease and therefore, renal 
hypoperfusion, will result in greater risk of non-HRS-AKI.  
 
Biomarkers of AKI 
Biomarkers are being investigated and assessed in order to discriminate between 
differing phenotypes of AKI, to allow earlier diagnosis of AKI and to aid in 
prognostication. Biomarkers of tubular injury may allow differentiation of functional 
from ischaemic injury which is important in managing AKI and determining which 
patients should be considered for certain therapies.  Following volume expansion 
those with HRS-AKI should receive a trial of vasopressors,69 whereas those with 
non-HRS-AKI should be considered for support if required and when appropriate 
with Renal Replacement Therapy (RRT).53   
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Using Serum Creatinine to define AKI in cirrhotic patients 
The use of Scr in cirrhosis is affected by several factors which hinder its utility as a 
marker of renal function.  The amount of creatinine produced each day is related to 
the muscle mass and physical activity, which are often reduced in patients with 
cirrhosis,70 thus creatinine values in cirrhotics are lower and smaller rises are likely to 
reflect a larger degree of renal dysfunction. Tubular secretion of creatinine is 
increased in cirrhotics,71 rendering SCr a less accurate measure of renal function. 
Scr is measured as a concentration so is affected by volume status, such as in those 
with significant fluid shifts or fluid overload,72 this is especially relevant in 
decompensated cirrhotics who often have ascites and or peripheral oedema. 
 
In practice, both chemical and enzymatic methods are used to measure creatinine in 
body fluids, with most clinical laboratories in the US and UK currently using 
variations of the Jaffe reaction; a method of which there are multiple variations. Many 
of the modifications have been undertaken to improve the specificity of the reaction, 
as the Jaffe reaction is not specific for creatinine: other compounds that may 
produce a Jaffe-like chromogen include proteins,73, 74  glucose, ascorbic acid75 
ketone bodies,76 pyruvate, guanidine, haemoglobin F, blood-substitute products77 
and cephalosporins.78 The degree of interference varies between individuals but 
collectively may account for 20% of measured ‘creatinine’ at physiological 
concentrations.79-81 More importantly for patients with cirrhosis bilirubin may interfere 
with laboratory creatinine assays due to spectral effects or reaction with assay 
reagents. Bilirubin is generally a negative interferent, with 5.8mg/dL (100 μmol/L) 
bilirubin reducing measured serum creatinine by 0.11-0.15mg/dL (10-15 μmol/L) in 
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three widely used commercial assays.74 An alternative approach has been to 
measure creatinine by enzymatic methods. The degree of interference with bilirubin 
is generally lower than that observed with Jaffe based assay.74 Although attempts to 
standardise measurements have been attempted, differences remain between 
assays and laboratories and these may contribute to differences in reporting AKI, 
and may lead to changes in clinical management.82-84 Relying on measurement of 
serum creatinine as a surrogate for renal function although practical and universally 
available, most likely provides an under appreciation of renal dysfunction in patients 
with cirrhosis. 
 
Biomarkers of AKI to help determine severity and distinguish subtypes 
Urinary Sodium  
Urinary sodium excretion is typically reduced in HRS, and the fractional excretion of 
sodium < 1%.  However, sodium excretion can be affected by diuretic administration. 
As such the fractional excretion of urea of ≥35 has been suggested to be more 
indicative of HRS and provide greater discrimination.53 
 
Novel biomarkers 
A number of biomarkers associated with AKI have been recently described, including 
serum cystatin C, urinary and serum Neutrophil Gelatinase Associated Lipocalin 
(NGAL), urinary IL-18, kidney Injury Molecule (KIM-1), liver type fatty acid binding 
protein, insulin like growth factor (IGFBP7) and tissue inhibitor metalloproteinase 
(TIMP2) (Table 5).85-87 NGAL has been the most widely studied of these novel 
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biomarkers. It is a small protein whose renal expression is upregulated following 
ischaemic or nephrotoxic insult resulting in higher concentrations in urine and serum. 
Although urinary NGAL levels demonstrated utility in differentiating between pre-
renal azotemia, HRS and intrinsic acute kidney injury,87-89  there remain limitations 
because of significant overlap between NGAL values and the types of AKI. The 
phenotype of AKI in the NGAL studies are based on clinical criteria not renal biopsy 
data, so correlation with NGAL relates not necessarily to differing underlying 
pathophysiology but to current clinical definitions of disease phenotypes. 
 
Studies to date have shown that these novel biomarkers increase with severity of 
liver injury and are predictive of outcomes.90, 91 Biomarkers are increased in both 
cases of HRS-AKI and non-HRS AKI. However, levels tend to be greater for non-
HRS AKI compared to HRS, but with a marked degree of overlap reported in most 
studies. In addition, urinary infection, which is more prevalent in patients with ACLF, 
also potentially increases urinary biomarker excretion. As such further study is 
required before biomarkers, and changes in biomarker levels can aid in 
differentiating HRS from AKI and lead to change in clinical outcomes.92   
 
Treatment 
Management of AKI in ACLF requires a multifaceted approach, providing support to 
failing organs, preventing further deterioration or progression of ACLF or AKI, whilst 
ensuring that any precipitant is promptly identified and treated. ACLF is associated 
with high mortality, thus management in a critical care setting is recommended as 
the optimal setting.93 Assessing intra-vascular volume status is an initial key step 
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with a view to ensuring any hypovolaemia is adequately treated. Volume status is 
challenging when managing patients with cirrhosis because of the hyperdynamic 
circulation, low systemic vascular resistance coupled with the common finding of 
ascites with or without peripheral oedema. There is only a limited role for central 
venous pressure (CVP) monitoring given the poor relationship with intravascular 
volume or response to fluid challenge.94 In addition, the presence of ascites results in 
a higher CVP without a corresponding increase in ventricular preload. Crystalloids 
may be used as initial fluid resuscitation but the use of hydroxethyl starch is 
contraindicated as its use has been associated with increased risk of AKI and 
mortality.95 In the general ICU setting volume resuscitation with albumin compared to 
crystalloids does not reduce mortality or risk of AKI,96 however in cirrhotic patients  
albumin is likely to have several theoretical advantages given the additional anti-
oxidant and anti-inflammatory properties of albumin over and above the oncotic 
pressure it exerts as a plasma protein.97 Treatment of SBP with albumin infusions at 
1.5g per Kg on day 1 and 1g per kg on day 3 in addition to antibiotics has been 
shown to reduce the occurrence of both AKI and mortality.98 Cirrhosis associated 
immune dysfunction is in part mediated by prostaglandin E2, which suppresses 
macrophage pro-inflammatory cytokines and bacterial killing in vitro, and albumin 
reduces Prostaglandin E2 bioavailability in vitro and attenuates prostaglandin E2 
mediated immunosuppression.99 
 
After excluding obstruction, then if renal function does not improve following simple 
volume expansion, the differential diagnosis of volume-unresponsive AKI can be 
classified into one of two groups; HRS-AKI or non-HRS-AKI. If AKI is associated with 
hypotension such as in sepsis or critically ill patients vasopressors may be utilised, 
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as they are conventially thought to improve mean arterial pressure (MAP) and hence 
renal blood flow. However, it is now recognised that sepsis associated AKI may be 
associated with increased renal blood flow and low urine output, which is thought to 
occur due to maldistribution or shunting of intra-renal blood flow. 100 Ensuring 
adequate renal perfusion is essential; however, targeting higher MAPs of 80-85 
mmHg compared to lower target MAPs 65-70mmHg in an ICU setting has been 
shown to have similar outcomes including rates of AKI.101  
 
The principal treatment strategy in HRS-AKI is to raise the low cardiac output and 
mean arterial pressure (MAP)102 by increasing the effective circulating volume 
through use of intravenous albumin combined with systemic vasoconstrictors to 
counter arterial vasodilatation and pooling in the splanchnic circulation. Albumin has 
been used successfully with a number of different vasoconstrictors; vasopressin 
analogues (terlipressin), alpha-adrenergic agonists (norepineprine) and a 
combination of somatostatin analogue (octeotride) and the alpha adrenergic agonist 
(midodrine), successfully to reverse HRS-AKI (Table 6). Although albumin doses 
have varied between studies, a recent meta-analysis indicates a key aspect of 
successful albumin therapy in HRS appears to be the cumulative dose.39 This meta-
analysis included 19 studies totalling 574 patients and observed a dose response 
relationship between the amount of infused albumin and survival, with significant 
improvement in survival associated with 100g increments in cumulative albumin 
dose over the range of cumulative albumin doses between 200g and 600g 
independent of treatment duration, vasoconstrictor type or MAP.39  In HRS-AKI 
patients with large volume ascites, abdominal paracentesis followed by albumin 
infusion improves creatinine clearance likely through reduction in intra-abdominal 
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pressure and improved renal blood flow as indicated by decreased renal resistive 
indices.103  
 
Several studies have shown that an improvement in systemic haemodynamics 
through a raised MAP in response to systemic vasoconstrictor therapy is associated 
with and predictive of HRS-AKI and the degree of improvement in MAP correlated 
with improvement in renal function.104  The early studies of vasoconstrictor use for 
HRS-AKI were limited by retrospective design and small numbers of patients,105-112  
with the same confounders also affecting the vast majority of randomised controlled 
trials (RCTs) (table 6). Terlipressin has been the vasoconstrictor most studied, and 
has greater affinity for V1 receptors in the splanchnic bed than V2 receptors in the 
kidney, leading to greater splanchnic vasoconstriction than renal.113 Terlipressin is 
not available in the USA or Canada for the treatment of HRS, thus norepinephrine or 
combination of octeotride and midodrine are used as alternatives. Two meta-
analyses have demonstrated that norepinephrine is equally as efficacious as 
terlipressin for reversal of HRS with no difference in 30-day survival.114, 115  Although 
some studies reported a benefit of octeotride and midodrine in conjunction with 
albumin for HRS-AKI,69, 116  a randomised controlled trial  (RCT) of terlipressin 
versus a combination of octeotride and midodrine demonstrated that terlipressin was 
a superior treatment with a significantly higher rate of recovery of renal function 
(70.4%) versus (28.6%).117  Recently the largest RCT of terlipressin for HRS-AKI 
(n=196)118 showed benefit for terlipressin over placebo but this did not reach 
statistical significance either for complete reversal of HRS-AKI (19.6 % vs. 13.1 %, 
P= 0.22) or partial HRS-AKI reversal (23.7% vs. 15.2%, P=0.13). The rate of HRS-
AKI reversal was significantly less than that in earlier RCTs119-121 which may be due 
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to a shorter duration of terlipressin treatment, up to 1/3 patients had ≤3 days of 
terlipressin administration, and relatively higher use of renal replacement therapy 
and liver transplantation compared to earlier studies.122  Nevertheless as most HRS-
AKI occurs in the setting of ACLF, the results of this study should serve as a catalyst 
to shift the treatment paradigm from solely haemodynamics to targeting systemic 
inflammation, the hallmark of ACLF.122  
 
Severity of ACLF predicts poor response to terlipressin and albumin in HRS-AKI,54-56  
thus therapies which potentially ameliorate the severity of ACLF by modulating the 
immune system such as mesenchymal stem cell therapy,123 Granulocyte Colony–
Stimulating Factor124  or plasmapheresis may potentially have a future role. Severity 
of ACLF is also strongly predictive of mortality, grade 3 ACLF (3 organ failure) is 
associated with 75% 28 day mortality,3 and maybe useful if prognostic decisions 
regarding treatment utility such as us the use of renal support in cases of HRS-AKI 
and multi-organ failure. Renal replacement in HRS-AKI is controversial125 with a 
consensus statement from the ADQI group recommending withholding renal support 
unless there is an acute reversible component or plan for liver transplantation given 
the lack of evidence showing any survival benefit of RRT in HRS-AKI.53, 126  The use 
of extra corporeal albumin dialysis such as Molecular Adsorbent Recirculation 
System (MARS) has been trialled in HRS-AKI on the basis that clearance of albumin 
bound vasodilators may improve outcomes, but clinical studies have so far failed to 
confirm any survival advantage.127   
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Currently liver transplantation affords the only therapeutic modality, which cures end 
stage liver disease and leads to reversal of AKI.128, 129 Overall one and five year 
outcomes of liver transplantation in the context of pre-transplantation AKI have been 
reported as 77% and 69%, respectively.130 A retrospective study of liver 
transplantation in patients with ACLF and AKI found one and five year survival of 
75% and 72% in those without renal dysfunction compared to 61% at one and five 
years with HRS.131 Pre- transplant renal function is predictive of post- transplant 
renal dysfunction with shorter duration of HRS (<4 weeks) associated with better 
outcomes128, 132 but in those with a higher risk of renal non-recovery such as 
sustained AKI greater than 6 weeks simultaneous liver kidney transplant should be 
considered.53   
 
Conclusion and future perspectives 
ACLF is a relatively newly recognised syndrome marked by systemic inflammation, 
which is altering our understanding of the pathogenesis of organ failure, especially 
renal failure. Current diagnostic criteria do not allow accurate distinction between 
HRS-AKI and non-HRS-AKI in ACLF patients and the available urinary biomarkers 
are limited in their ability to do so. Earlier diagnosis of the cause of AKI may help 
treatment of HRS. Prevention of progression of HRS to acute tubular injury remains 
an unmet need and despite the ability of terlipressin and albumin to reverse HRS in 
about 40% patients, mortality rates are not influenced significantly. Therefore, 
strategies for renal protection need to be developed. Inflammation is increasingly 
recognised as an important driver of AKI, particularly in patients with associated 
infection and multiorgan failure. Novel therapies are needed as terlipressin and 
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albumin are ineffective in this situation. As AKI that is persistent, rapidly becomes 
irreversible, then novel approaches are required to allow tubular regeneration to 
avoid the need for combined liver and kidney transplantation.   
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Table 1. International Club of Ascites (ICA) Diagnostic criteria for hepatorenal 
syndrome (HRS) 
 
 
Table 3 Grading of ACLF 
 
 
 
 
 
HRS-AKI Diagnosis 
 
• Diagnosis of cirrhosis and ascites 
• Diagnosis of acute kidney injury (AKI) according to ICA-AKI criteria 
• No response after 2 consecutive days of diuretic withdrawal and plasma 
volume expansion with albumin 1 g per kg of body weight 
• Absence of shock 
• No current or recent use of nephrotoxic drugs  
• No macroscopic signs of structural kidney injury*, 
defined as: 
- absence of proteinuria (>500 mg/day) 
- absence of microhaematuria (>50 RBCs per high 
power field), 
- normal findings on renal ultrasonography 
40 
 
Table 2 – International Club of Ascites (ICA) definition and grading of acute 
kidney injury (AKI) in patients with cirrhosis 
Stage of AKI Definition 
1 Increase in Serum Creatinine ≥0.3 mg/dl (26.5 μmol/L) or an 
increase in Serum Creatinine ≥1.5-fold to 2-fold from baseline 
2 Increase in Serum Creatinine >2-fold to 3-fold from baseline 
3 Increase of in Serum Creatinine >3-fold from baseline or in Serum 
Creatinine ≥4.0 mg/dL (353.6 μmol/L) with an acute increase ≥0.3 
mg/dl (26.5 μmol/L) or initiation of renal replacement therapy 
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Table 3. Diagnostic Criteria for Acute on Chronic Liver Failure (ACLF) 
A. Definition of organ failure for the diagnosis of ACLF 
 
Organ System Score = 1 Score = 2 Score = 3 
Liver  
(bilirubin mg/dl) 
Bilirubin < 6 6 ≤ Bilirubin ≤ 12 Bilirubin >12 
Kidney  
(creatinine 
mg/dl) 
Creatinine  <2 Creatinine ≥2 <3.5 Creatinine ≥3.5 or 
renal replacement 
Brain  
(West-Haven 
criteria) 
Grade 0 Grade 1-2 Grade 3-4 
Coagulation 
INR 
INR < 2.0 2.0 ≤ INR < 2.5 INR ≥ 2.5 
Circulation 
Mean arterial 
pressure mmHg 
MAP ≥70 MAP <70  Vasopressors 
Respiratory: 
PaO2/FiO2 
 or SpO2/FiO2  
>300 
>357  
≤300 - > 200 
>214- ≤357  
≤200 
≤214  
Values obtained at hospital admission. Shaded area represents organ failure. International 
normalised ratio (INR), arterial oxygen tension mmHg (PaO2), inspired oxygen concentration (FiO2), 
pulse oximetry oxygen saturation (%) (SpO2). 
 
 
B. Diagnostic criteria and Grading of Acute on Chronic Liver Failure (ACLF) 
 
ACLF Grade Definition 
No ACLF (a) Patients with no organ failure 
(b) Patients with single hepatic, coagulation, circulation or respiratory failure, 
serum creatinine <1.5 mg/dl and no HE 
(c) Patients with cerebral failure and creatinine <2mg/dl 
ACLF Grade 1 (a) Patients with renal failure 
(b) Patients with other single organ failure with (a) serum creatinine ≥1.5 and<2 
mg/dl and/or (b) HE grade 1-2.   
ACLF Grade 2  Two organ failures 
ACLF Grade 3 Three organ failures or more 
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Table 4. Hepatorenal syndrome-acute kidney injury (HRS-AKI) and non-HRS-
AKI as causes of AKI in Acute on Chronic Liver Failure (ACLF) patients.  
Characteristic HRS  Non HRS-AKI 
History of decompensated 
Cirrhosis and ascites 
Common and almost 
invariable 
Not necessary 
Systemic Haemodynamics Reduction of Effective 
arterial blood volume +++ 
Reduction of Effective 
arterial blood volume + 
Cardiac Output Increased, rarely reduced Variable 
Requirement for 
vasopressors 
Rare Common 
Renal Blood Flow Reduced +++ Reduced + 
Renal Blood Flow 
autoregulation 
Shifted to the right +++ Unknown 
Appearances of renal 
Histology 
Normal Evidence of renal tubular 
injury and cell death, 
inflammatory cell 
infiltration, increased 
expression of TLR4 in the 
tubules 
Extra renal organ failure Rare Common 
Bile acid nephropathy Rare Common 
Systemic Inflammatory 
response  
Rare Common 
Proteinuria (>500gr/day) No Usually present 
Urinary Biomarkers 
   NGAL 
   IL-18 
   TLR4 
May be increased  Typically increased  
Response to Terlipressin 
and Albumin 
Yes Unknown 
Need for Renal 
Replacement Therapy 
Rare Usual 
 
neutrophil gelatinase associated lipocalin (NGAL), interleukin (IL), Toll like receptor (TLR4),   
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Table 5. Biomarkers that have been studied to differentiate acute kidney injury 
(AKI) caused by tubular injury compared to other causes of AKI 
Biomarker Origin Limitations 
Neutrophil gelatinase-
associated lipocalin 
(NGAL) 
Kidney – tubular protein, release 
caused by cell damage 
- Increased levels in inflammation. 
- Significant  overlap in values between 
AKI groups 
-  Small quantities produced by the Llver  
Interleukin 18 (IL-18) Monocytes and macrophages 
(pro-inflammatory) 
- Significant  overlap in values between 
AKI groups 
- Increased in Sepsis and Systemic 
Inflammation of any cause 
- Pathophysiologically, inflammatory cell 
infiltration is not a major components of 
ATI in cirrhosis 
Kidney Injury Molecule 
-1 (KIM-1) 
Kidney - Tubular 
transmembrane protein 
upregulated by injury 
- Significant  overlap in values between 
AKI groups 
- Data do not allow distinction between 
HRS and ATI 
 
Liver-type Fatty-acid 
binding protein  
(L-FABP) 
Kidney – proximal tubule, 
upregulated by cell injury 
- Increased in CKD and sepsis 
Trefoil Factor 3 (TFF-
3) 
Epithelial cells - Increased in CKD and inflammatory 
conditions, 
Limited data in cirrhosis 
Glutathione-S-
transferase-π (GST-π) 
Kidney- tubular protein, release 
caused by cell damage to 
tubular epithelial cells 
- Limited data in cirrhosis 
- Cannot distinguish between ATI and 
HRS 
Urinary Toll Like 
receptor 4 
Kidney tubular epithelium in 
cirrhosis  
- The test is semi-quantitative 
- Limited data 
 
Hepatrorenal syndrome (HRS) 
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Table 6 – Randomised controlled trials s of albumin and vasoconstrictors for 
treatment of hepatorenal syndrome (HRS) type 1 
Author Year Treatment/comparative 
group 
n (% 
HRS 
Type 1) 
Albumin HRS 
reversal 
% 
Survival 
(%) 
Solanki et al. 
133 
2003 Terlipressin 24 
(100%) 
40 g/day 
to keep 
CVP 10–
12 
42 42 
Placebo 0 0 
Alessandria 
et al. 134 
2007 Terlipressin 22 
(41%) 
To keep 
CVP 10 -
15 
83 92 
Noradrenalin 70 80 
Neri et al. 121 2008 Terlipressin 52 
(100%) 
1 g/kg 
then 20 –
40 g/day 
81 42 
Placebo 19 15 
Martin-Llahi 
et al. 120 
2008 Terlipressin 46 
(56%) 
1 g/kg 
followed 
by 20-40 
g/day 
44 27 
Placebo 9 19 
Sanyal et 
al.119  
2008 Terlipressin 112 
(100%) 
1 g/kg 
then 25 
g/day 
34 13 
Placebo 13 9 
Sharma et al. 
135 
2008 Terlipressin 40 
(100%) 
To keep 
CVP 10–
12 
50 45 
Noradrenalin 50 45 
Singh et al. 
136 
2012 Terlipressin 46 
(100%) 
20g/day 39 39 
Noradrenalin 43 48 
Cavallin et al. 
117 
2015 Terlipressin 49 
(92%) 
1 g/kg 
followed 
by 20-40 
g/day 
70 70 
Midodrine and Octeotride 29 59 
Srivastava et 
al. 137 
2015 Terlipressin  40 
(100%) 
20g /day - 21 
Dopamine and furosemide - 20 
Boyer et al. 
_118 
2016 Terlipressin 196 
(100%) 
20-
40g/day 
20 58 
Placebo 13 55 
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Figure legends 
 
Figure 1 Proposed classification of acute-on-chronic liver failure.  
Acute-on-chronic liver failure, which can develop after a precipitating insult in patients with 
non-cirrhotic chronic liver disease (type A) or compensated (type B) or decompensated (type 
C) cirrhotic liver disease.  
Adapted from Jalan et al. (2014) [4]. 
 
Figure 2. Pathogenesis of Hepatorenal Syndrome in patients with Acute on Chronic Liver 
Failure (ACLF). 
 
Figure 3. Pathogenesis of Acute Tubular Injury in Acute on Chronic Liver Failure (ACLF). 
 patients (modified from Jalan et al. J Hepatol 2014). 
 
Figure 4. Evidence of ATI in patients with non-HRS associated renal failure and 
demonstration of apoptosis as a cause of cell death in patients with non-HRS renal failure 
(reproduced from Shah et al. Liver International 2013) 
 
 
 
 
 
